ALOX5 and asthma: The most convincing evidence for an etiological role of cysteinyl-LTs in asthma comes from the therapeutic efficacy of CysLT1 receptor antagonists (e.g., montelukast, zafirlukast, pranlukast), commonly known as leukotriene receptor antagonists (LTRAs), and 5-lipoxygenase (5-LO) inhibitors (e.g., zileuton) in patients with asthma [4].